Sofia Genta

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

María Vieito, Víctor Moreno, Anna Spreafico et al. · Clinical Cancer Research · 2023 · 77 citations

Medicine, Pharmacokinetics, Pharmacology +17

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

Eleonora Ghisoni, Furio Maggiorotto, Fulvio Borella et al. · Journal of Ovarian Research · 2019 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Ilaria Colombo, Sofia Genta, Federica Martorana et al. · Clinical Cancer Research · 2021 · 33 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom, Albiruni Abdul Razak, Matthew H. Taylor et al. · Clinical Cancer Research · 2024 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16

Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).

Sofia Genta, Sareh Keshavarzi, N. Yee et al. · Journal of Clinical Oncology · 2022 · 26 citations

Life Sciences, Immunology, Oncology +17